News

1 2
NEWS

SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline

  • PPF Group provides funding to advance SOTIO through key clinical milestones
  • Proceeds shall be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial
  • Three programs (SOT102, BOXR1030, and SOT201) to advance through phase 1

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that is has secured €280m of funding to significantly expand and advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs until end of 2023.